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Quinolone Safety
and Efficacy
To the Editor: Richard Frothing-
ham should be commended for pro-
viding added perspective on the mat-
ter of quinolone selection. His letter to
the editor emphasizing the paramount
importance of a well-established safe-
ty profile and documented clinical
efficacy in severe infections before a
“wholesale change” to the newer
quinolones is an appropriate response
to Michael Scheld’s essay on main-
taining quinolone class efficacy in
which a “correct spectrum” strategy
of using the most potent quinolone to
treat the presumed or confirmed
pathogen was described and advocat-
ed (1). In his article, Frothingham
reminds us that serious adverse drug
effects in patients led to the withdraw-
al or restriction of 4 quinolones in the
last decade and that safety may differ
substantially among the quinolones
discussed in Scheld’s review
(ciprofloxacin, gatifloxacin, levoflo-
xacin, moxifloxacin) (2).
With the exception of labeling
changes regarding glucose homeosta-
sis abnormalities associated with gati-
floxacin therapy, the subject of
quinolone safety is centered on tor-
sades de pointes. Data published in
2001 are cited; these consist of a
review of crude rates of US cases of
torsades de pointes from January
1996 through May 2, 2001 (3).
However, these data only capture
adverse drug reports for the first full
year gatifloxacin and moxifloxacin
were widely available in the United
States. The last several years have
seen dramatic uptake of all 3 respira-
tory quinolones. Use of these agents is
pervasive in both community and hos-
pital settings. Indeed, the Infectious
Diseases Society of America,
American Thoracic Society, and Sinus
and Allergy Health Partnership have
since published revised consensus
statements calling for the use of these
agents earlier in therapy for commu-
nity-acquired pneumonia and bacteri-
al sinusitis (4–6).
December 2004 marked 5 years
since the Food and Drug Admini-
stration approved gatifloxacin and
moxifloxacin and 8 years since the
approval of levofloxacin. As a result
of tens of millions of patient expo-
sures, we now have more robust data
to work with and are better able to
make informed and meaningful safety
comparisons, particularly with respect
to torsades de pointes, a rare, life-
threatening cardiac arrhythmia infre-
quently associated with quinolone
therapy. 
With respect to efficacy, Frothing-
ham writes that ciprofloxacin and lev-
ofloxacin have been studied in patient
populations with more severe illness,
and trials of the newer quinolones
have enrolled patients with predomi-
nantly mild or moderate community-
acquired infections and low overall
death rates in comparison. However, a
cursory review of the literature sug-
gests otherwise. As with gatifloxacin
and moxifloxacin, few peer-reviewed,
published data support the use of lev-
ofloxacin in the treatment of severe,
life-threatening infections at the cur-
rently approved doses of 500 mg or
750 mg. 
Indeed, the 2 references cited raise
serious concern about the suitability
of levofloxacin at currently recom-
mended doses for severe and life-
threatening infections. In File et al. (7)
levofloxacin was studied in only 16
patients classified as having severe
community-acquired pneumonia; in
Norrby et al. (8) a dose of lev-
ofloxacin 500 mg every 12 hours was
studied in severe community-acquired
pneumonia. At this time, other pub-
lished studies support the use of lev-
ofloxacin at a dose of 500 mg every
12 hours in severe and life-threaten-
ing infections: an approved regimen
in Europe but not yet approved in the
United States (9,10).
In summary, differences in quino-
lone safety are evidenced by labeling
changes to gatifloxacin, the only
quinolone to carry a specific warning
regarding glucose homeostasis abnor-
malities. However, the incidence of
torsades de pointes associated with
each of these agents is ripe for further
investigation as we pass the 5-year
mark of approval for the new respira-
tory quinolones. An update of those
data on the rate of torsades cited by
Frothingham and published in 2001
would provide meaningful guidance
to clinicians. Currently, with the
exception of ciprofloxacin, each of
these quinolones contains labeling
guidance in the form of a warning
(gatifloxacin, moxifloxacin) or a pre-
caution (levofloxacin), and concurrent
use with class IA(e.g., quinidine, pro-
cainamide) or class III (e.g., amio-
darone, sotalol) antiarrhythmics
should be avoided to reduce the risk
of torsades de pointes per current
product labeling. 
Ciprofloxacin remains the only
quinolone to date based on multiple,
head-to-head, well-controlled, pub-
lished trials to have established effica-
cy and safety in a severely ill patient
population at approved doses. A
paucity of published clinical data
exist on the use of gatifloxacin, lev-
ofloxacin and moxifloxacin in hospi-
talized patients with severe, life-
threatening infections. Therefore, the
respective manufacturers must estab-
lish safety and efficacy in well-con-
trolled studies with the resultant data
made available in peer-reviewed jour-
nals before these agents are fully
embraced for these infections.
Spartaco Bellomo*
*Christ Hospital, Jersey City, New Jersey,
USA
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In response: I agree. Expanding
clinical experience makes a reap-
praisal of quinolone safety and effica-
cy timely (1). Through December
2004, >160,000,000 ciprofloxacin,
69,000,000 levofloxacin, 12,000,000
gatifloxacin, and 11,000,000 moxi-
floxacin prescriptions were filled at
US retail pharmacies.
Dr. Bellomo requests an update of
my previous report on torsades de
pointes adverse drug events (ADEs)
(2). I reviewed 16,868 U.S. Food and
Drug Administration ADE reports
associated with these 4 quinolones
from November 1997 to September
2003 (3). My review identified the fol-
lowing numbers of unique US torsades
de pointes ADEs: 3 ciprofloxacin, 51
levofloxacin, 37 gatifloxacin, and 20
moxifloxacin. Ciprofloxacin or non-
quinolone antimicrobial drugs should
generally be selected for patients with
risk factors for QT interval prolonga-
tion (4-7).
Numerous published trials and
extensive clinical experience support
the safety and efficacy of
ciprofloxacin. Generic oral
ciprofloxacin is inexpensive. These
factors make ciprofloxacin the
quinolone of choice for nonrespirato-
ry infections.
Gatifloxacin is associated with
hypoglycemia and hyperglycemia
ADEs, including death, at rates great-
ly exceeding those of other
quinolones (3). A causal relationship
between gatifloxacin and these ADEs
is supported by animal data (8), man-
ufacturer safety cohort studies (5), in
vitro assays (9), a large randomized
trial (10), and >20 published case
reports. Gatifloxacin has no meaning-
ful cost or efficacy advantage to bal-
ance this excess risk.
Clinical experience continues to
support the safety of levofloxacin and
moxifloxacin. Apart from torsades de
pointes, my review did not identify
specific safety concerns. Both drugs
are effective for community-acquired
respiratory infections, although clini-
cal experience and published data are
more extensive of levofloxacin than
moxifloxacin. Levofloxacin has
received FDAapproval for nosocomi-
al pneumonia (6). Dr. Bellomo notes
that levofloxacin trials have used a
variety of dosages; the optimal dosage
for serious infections is unknown.
Moxifloxacin has greater activity
against  Streptococcus pneumoniae,
which could possibly prevent the
emergence of resistance or lead to
faster clinical responses in pneumo-
coccal infections. Both moxifloxacin
and levofloxacin are appropriate
choices for community-acquired res-
piratory infections.
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